Wednesday, June 30, 2010

Calistoga Pharmaceuticals Gains $40M More

Seattle-based Calistoga Pharmaceuticals, a developer of treatments for cancer and inflammatory disease, said today that it has raised $40M more in a Series C financing round. The round was led by Quogue Capital, and also included prior investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners, along with new investor Latterell Venture Partners. The firm said the funding will go to advance its pipeline. Calistoga Pharmaceuticals is developing biopharmaceuticals based on isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors. The firm is currently looking to apply that technology to the treatment of non-Hodgkin's lymphona, mantle cell lymphona, and chronic lymphocytic leukemia. More information »